Phase 4
Completed N=55
Surgical Pain Control With Ropivacaine by Atomized Delivery
Source: ClinicalTrials.gov NCT01480089 ↗Enrolled (actual)
55
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcomePrimary: Post-op Pain With Atomized Intraperitoneal Ropivacaine (AIR) — 2.536; 3.844 millimeters — p=.098
◆ Published Evidence
Emerging
12citations · ~1 / year
Surgical Pain Control With Ropivacaine by Atomized Delivery (Spray): A Randomized Controlled Trial.
Summary
The purpose of this trial is to determine the effect of spraying a local anesthetic called Ropivacaine (numbing medicine) into the abdominal cavity prior to surgery. Ropivacaine is a local anesthetic used to block pain in the body. There are studies showing that Ropivacaine decreases the pain of surgery with minimally invasive (laparoscopic) appendix and gallbladder removal but has not been tried in robotic pelvic surgery.
Linked Publications
-
Surgical Pain Control With Ropivacaine by Atomized Delivery (Spray): A Randomized Controlled Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Post-op Pain With Atomized Intraperitoneal Ropivacaine (AIR) |
2.154; 2.219 | .90 |
| SECONDARY Post-op Pain With Atomized Intraperitoneal Ropivacaine (AIR) |
2.154; 2.219 | .90 |
Eligibility Criteria
Inclusion Criteria
- Consent to undergo robotic assisted gynecologic or urologic surgery
- Between the ages of 18 and 75
- Able to consent, fill out study documents, and complete all study procedures and follow-up visits
Exclusion Criteria
- Patients with an allergy to local anesthetics
- Patients with severe underlying cardiovascular, renal or hepatic disease
- Pregnant patients
Data sourced from ClinicalTrials.gov (NCT01480089) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.